Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
Completed · Phase 1 · Has a placebo group
Conditions studied: Colorectal Cancer, Precancerous Condition
In brief
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib may keep polyps and colorectal cancer from forming in patients with familial adenomatous polyposis. PURPOSE: This randomized phase I trial is studying the side effects and best dose of celecoxib in treating young patients with a genetic predisposition for familial adenomatous polyposis.
Key facts
- Study ID
- NCT00685568
- Run by
- M.D. Anderson Cancer Center
- People needed
- 22
- Starts
- 2002-11-21
- Expected to finish
- 2006-04-21
- Last updated by the study team
- 2018-11-07
Who can join
Age: 10 and older, up to 14. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
- Texas Children's Hospital — Houston, Texas, United States
- University of Texas Medical School at Houston — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.